SGEN
NASDAQSeagen Inc.
News · 26 weeks10%
2025-12-142026-06-07
Mix090d
No activity.
Latest news
25 items- PRBiliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsightLAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current
- PRAlltrna Announces Updates to Its Board of DirectorsChris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
- NEWSOutdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing TreatmentPfizer Inc (NYSE:PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several top-sellers. At the end of 2023, Pfizer completed its acquisition of Seagen Inc. (NASDAQ:SGEN), a biotechnology leader in transformative cancer medicines. Although Pfizer still has a few growth best-sellers, migraine therapy Nurtec and respiratory syncytial virus (RSV) vaccine, Pfizer is betting on such big business development deals to boost its annual revenue by close to $25 billion by the end of the decade. Last year, the U.S. FDA also approved Pfizer’s blood cancer therapy. But cancer is one of
- NEWSHow To Earn $500 A Month From Pfizer StockPfizer Inc. (NYSE:PFE) shares closed almost flat on Friday, but lost around 44% during 2023. Pfizer recently announced the completion of its acquisition of Seagen Inc (NASDAQ:SGEN) for $229 per share at a total value of approximately $43 billion. Pfizer recently provided its full-year 2024 guidance, which includes the expected financial impact from the Seagen transaction. For FY24, the pharma giant expects revenue of $58.5 billion-$61.5 billion, including the expected contribution from the Seagen acquisition versus the consensus of $63.17 billion. With the recent buzz around Pfizer, some investors may be eyeing potential gains from the company’s dividends. As of now, Pfizer offers an ann
- NEWSUpward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023. Deal volume fell 9% from 242 deals in Q2 2023 to 221 M&A deals in Q3 2023. PricewaterhouseCoopers wrote in its Pharmaceutical and Life Sciences: U.S. Deals 2024 Outlook. "As regulators' perspectives on key deal factors become better understood, there may be a return of larger deals, along with continued interest in the $5 billion to $15 billion deals to fill targeted strategic gaps." "Despite some stabilization in the macroeconomic environment and the potential for a soft landing in sight, continued geopolitical and regulatory uncertainty
- SECSEC Form 15-12G filed by Seagen Inc.15-12G - Seagen Inc. (0001060736) (Filer)
- INSIDERBaker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Seagen Inc. (Amendment)SC 13D/A - Seagen Inc. (0001060736) (Subject)
- INSIDERHimes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- INSIDERSimonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- INSIDERSimpson Todd E returned $21,363,868 worth of shares to the company (93,292 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- INSIDERLove Ted W returned $974,395 worth of shares to the company (4,255 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- INSIDERSwain Sandra M returned $178,162 worth of shares to the company (778 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- INSIDERLiu Jean I returned $11,163,292 worth of shares to the company (48,748 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- INSIDERWelch Daniel G returned $3,543,775 worth of shares to the company (15,475 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- INSIDEREpstein David R returned $3,757,203 worth of shares to the company (16,407 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- INSIDERSeth Alpna returned $2,966,237 worth of shares to the company (12,953 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- INSIDERGryska David W returned $11,221,687 worth of shares to the company (49,003 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- INSIDERSEC Form 4 filed by Romp Charles R4 - Seagen Inc. (0001060736) (Issuer)
- INSIDEROrwin John A returned $6,641,687 worth of shares to the company (29,003 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- INSIDERDansey Roger D returned $8,779,402 worth of shares to the company (38,338 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- INSIDERRomp Charles R returned $7,739,284 worth of shares to the company (33,796 units at $229.00), closing all direct ownership in the company (SEC Form 4)4 - Seagen Inc. (0001060736) (Issuer)
- NEWSPfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 ForecastTruist Securities analyst Robyn Karnauskas reiterated a Buy rating on Pfizer, Inc. (NYSE:PFE), lowering the price target to $36 from $42. While PFE provided lower-than-expected 2024 guidance, primarily driven by the management's conservative $8 billion COVID-19 product forecast, the analyst sees longer-term growth from investment in oncology with the Seagen Inc. (NASDAQ:SGEN) acquisition. According to the analyst, PFE is in execution mode, headed towards its 2030 vision following recent launches and BD deals. In addition, Seagen provides Pfizer with an array of proven and promising candidates, catapulting PFE to significant growth in 2030. PFE's FY2024 revenue guidance of $58.5 billion
- SECSEC Form S-8 POS filed by Seagen Inc.S-8 POS - Seagen Inc. (0001060736) (Filer)
- SECSEC Form S-8 POS filed by Seagen Inc.S-8 POS - Seagen Inc. (0001060736) (Filer)
SGEN FAQ
7 questionsWhat does Seagen Inc. do?
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic...Where does SGEN stock trade?
Seagen Inc. (SGEN) is listed on NASDAQ.What sector and industry is SGEN in?
Seagen Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Seagen Inc. go public?
Seagen Inc. (SGEN) completed its IPO in 2001.What are analysts saying about SGEN?
Seagen Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform on 2023-02-16.What companies are similar to SGEN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare SGEN side-by-side with any of them on Quantisnow.How can I track SGEN on Quantisnow?
Quantisnow aggregates Seagen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SGEN to receive live email and push alerts on every new disclosure.